Table 3.

Sub-group analyses of the prevalence of MRSA amongst DFI patients

	Nation(s)	No. of data sets	No. of patients	Pooled prevalence %	95% CI	I2 (%)	95% CI
DFI patients	–	41	10994	16.78	13.21–20.68	96.16	95.43–96.77
Out-patients	–	6	2440	13.16	7.88–19.55	91.99	85.34–95.63
In-patients	–	28	7444	15.98	11.99–20.42	95.59	94.51–96.47
Central America	Costa Rica, Mexico	2	479	20.07	2.45–48.64	96.81	91.55–98.80
North Africa & The Middle East	Algeria, Egypt, Saudi Arabia, Turkey	4	746	17.25	0.63–49.16	98.62	97.83–99.12
Western Europe	France, Italy, Portugal, Spain	7	2295	16.96	9.77–25.63	94.96	91.83–96.89
Indian Subcontinent	India, Nepal, Pakistan	5	540	14.40	6.43–24.87	89.11	77.32–94.77
East Asia	China, Singapore, Taiwan	4	664	12.73	5.64–22.15	89.88	76.99–95.55
UK	–	4	333	19.59	13.88–26.01	49.56	0.00-83.31
India	–	3	357	18.34	10.06–28.44	78.91	32.51–93.41
USA	–	10	4893	14.70	8.54–22.18	97.29	96.25–98.05
France	–	4	1157	12.28	7.18–18.51	88.04	71.78–94.93
China	–	2	430	11.65	3.14–24.56	90.40	65.19–97.35

CI confidence interval